Dr. Dougan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114Phone+1 617-726-2865
Education & Training
Massachusetts General HospitalFellowship, 2013 - 2015- Massachusetts General HospitalResidency, 2011 - 2014
Harvard Medical SchoolClass of 2011
Certifications & Licensure
MA State Medical License 2017 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
Clinical Trials
- Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis Start of enrollment: 2020 Aug 31
Roles: Principal Investigator, Contact
- Vedolizumab for the Treatment of Collagenous Gastritis Start of enrollment: 2024 May 01
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 2 citationsEnhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes ...Virginia H Sun, Julius C Heemelaar, Ibrahim Hadzic, Vineet K Raghu, Chia-Yun Wu
Journal of Clinical Oncology. 2024-12-10 - 1 citationsAnti-LAG-3 boosts CD8 T cell effector function.Courtney T Kureshi, Michael Dougan, Stephanie K Dougan
Cell. 2024-08-08 - The Development of Persistent Gastrointestinal Symptoms in Patients With Melanoma Who Have Had an Immune Checkpoint Inhibitor-Related Gastrointestinal Toxicity.Sanskriti Varma, Keri Sullivan, Jamie DiCarlo, Alexandra Coromilas, Kyle Staller
Clinical and Translational Gastroenterology. 2024-08-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
